Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

According to lawyers at Ropes & Gray, Novo Nordisk misled doctors and consumers about availability of Sanofi's insulin drugs, Lantus and Toujeo. Sanofi-Aventis and its lawyers at Ropes & Gray are ...

Sanofi and its blockbuster drug Dupixent has by the thinnest of margins returned to the top spot for TV drug ad spending in October, beating out fierce rival AbbVie and its immunology drug Rinvoq, ...

Sanofi Consumer Healthcare is pushing back on a recommendation that it discontinue the “#1 doctor-recommended” claim for its Zantac 360° heartburn medicine in a case brought by competitor Johnson & ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent(dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) ...

Good-Loop -- which enables advertisers to measure the carbon emissions generated by their digital ad campaigns -- has inked a partnership with Integral Ad Science, which allows the company to ...

The FINANCIAL — Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic ...

Sanofi (ENXTPA:SAN) has been drifting lower recently, and that slide is starting to catch investors attention as they weigh short term weakness against long term growth in vaccines, immunology, and ...

Sanofi SAN-0.51%decrease; red down pointing triangle plans to buy assets from biopharmaceutical company Inhibrx INBX 1.10%increase; green up pointing triangle in a deal worth up to $2.2 billion as it ...